| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1038510794 |
| P356 | DOI | 10.1007/S11882-016-0610-0 |
| P698 | PubMed publication ID | 26942731 |
| P2093 | author name string | Stacie M Jones | |
| Robbie D Pesek | |||
| P2860 | cites work | Oral immunotherapy for milk allergy | Q24202867 |
| Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract1 | Q28243179 | ||
| Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel | Q28300001 | ||
| A phase II, randomized, double‑blind, parallel‑group, placebo‑controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy | Q28307175 | ||
| Fatalities due to anaphylactic reactions to foods | Q31812490 | ||
| A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy | Q33574876 | ||
| Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3). | Q33999649 | ||
| Safety and feasibility of oral immunotherapy to multiple allergens for food allergy | Q34398080 | ||
| Changes in peanut-specific T-cell clonotype with oral immunotherapy | Q34474520 | ||
| Strain-dependent induction of allergic sensitization caused by peanut allergen DNA immunization in mice. | Q34502599 | ||
| Individualized IgE-based dosing of egg oral immunotherapy and the development of tolerance. | Q34517635 | ||
| Immunologic changes in children with egg allergy ingesting extensively heated egg. | Q34598352 | ||
| The psychosocial impact of food allergy and food hypersensitivity in children, adolescents and their families: a review. | Q34617096 | ||
| Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial | Q34628073 | ||
| Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization | Q34640733 | ||
| A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response | Q34698506 | ||
| Dietary baked milk accelerates the resolution of cow's milk allergy in children | Q35151908 | ||
| Milk oral immunotherapy is effective in school-aged children. | Q50919256 | ||
| High IgE levels to α-lactalbumin, β-lactoglobulin and casein predict less successful cow's milk oral immunotherapy. | Q51633397 | ||
| Oral Immunotherapy for Egg Allergy: A Double-Blind Placebo-Controlled Study, with Postdesensitization Follow-Up. | Q51654466 | ||
| Accidental allergic reactions in children allergic to cow's milk proteins. | Q51809026 | ||
| Oral peanut immunotherapy in children with peanut anaphylaxis. | Q52903267 | ||
| The prevalence, severity, and distribution of childhood food allergy in the United States. | Q53085704 | ||
| Early sustained unresponsiveness after short-course egg oral immunotherapy: a randomized controlled study in egg-allergic children. | Q53397405 | ||
| Oral immunotherapy in cow's milk allergic patients: course and long-term outcome according to asthma status. | Q53636045 | ||
| Life-threatening anaphylaxis to kiwi fruit: protective sublingual allergen immunotherapy effect persists even after discontinuation | Q79381574 | ||
| Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract | Q81454014 | ||
| Oral immunotherapy for cow's milk allergy with a weekly up-dosing regimen: a randomized single-blind controlled study | Q82340072 | ||
| Randomized double-blind, placebo-controlled trial of sublingual immunotherapy with a Pru p 3 quantified peach extract | Q83272498 | ||
| Cow's milk epicutaneous immunotherapy in children: a pilot trial of safety, acceptability, and impact on allergic reactivity | Q84183803 | ||
| Phl p 5 resorption in human oral mucosa leads to dose-dependent and time-dependent allergen binding by oral mucosal Langerhans cells, attenuates their maturation, and enhances their migratory and TGF-beta1 and IL-10-producing properties | Q84491603 | ||
| How adherent to sublingual immunotherapy prescriptions are patients? The manufacturers' viewpoint | Q84978808 | ||
| Safety and predictors of adverse events during oral immunotherapy for milk allergy: severity of reaction at oral challenge, specific IgE and prick test | Q85821530 | ||
| Clinical and laboratory 2-year outcome of oral immunotherapy in patients with cow's milk allergy | Q86517566 | ||
| Baseline specific IgE levels are useful to predict safety of oral immunotherapy in egg-allergic children | Q86980120 | ||
| Safety of epicutaneous immunotherapy for the treatment of peanut allergy: A phase 1 study using the Viaskin patch | Q87379787 | ||
| Intralymphatic immunotherapy | Q35155423 | ||
| A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients | Q35510416 | ||
| Suppression of the immunologic response to peanut during immunotherapy is often transient | Q35589449 | ||
| A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy | Q35603477 | ||
| Sublingual immunotherapy for peanut allergy: Long-term follow-up of a randomized multicenter trial | Q35923082 | ||
| Long-term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy | Q35939076 | ||
| Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis | Q35970094 | ||
| Allergic reactions to foods in preschool-aged children in a prospective observational food allergy study | Q36057506 | ||
| Rapid oral desensitization in combination with omalizumab therapy in patients with cow's milk allergy | Q36093954 | ||
| Oral immunotherapy for treatment of egg allergy in children | Q36180099 | ||
| The safety and efficacy of sublingual and oral immunotherapy for milk allergy. | Q36220764 | ||
| Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial | Q36548283 | ||
| A phase 1 study of heat/phenol-killed, E. coli-encapsulated, recombinant modified peanut proteins Ara h 1, Ara h 2, and Ara h 3 (EMP-123) for the treatment of peanut allergy | Q36874668 | ||
| Long-term follow-up of oral immunotherapy for cow's milk allergy | Q37138947 | ||
| A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow's milk allergy | Q37150568 | ||
| Evidence of pathway-specific basophil anergy induced by peanut oral immunotherapy in peanut-allergic children | Q37188523 | ||
| Clinical efficacy and immune regulation with peanut oral immunotherapy | Q37301616 | ||
| Safety of a peanut oral immunotherapy protocol in children with peanut allergy | Q37316978 | ||
| Food allergy among children in the United States | Q37633787 | ||
| Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy. | Q37649825 | ||
| Specific oral tolerance induction in food allergic children: is oral desensitisation more effective than allergen avoidance?: a meta-analysis of published RCTs. | Q37762634 | ||
| Oral immunotherapy for IgE-mediated cow's milk allergy: a systematic review and meta-analysis | Q37987177 | ||
| Effectiveness and safety of orally administered immunotherapy for food allergies: a systematic review and meta-analysis | Q38128925 | ||
| Sublingual immunotherapy for aeroallergens: status in the United States | Q38179107 | ||
| Update on immune mechanisms associated with sublingual immunotherapy: practical implications for the clinician | Q38190712 | ||
| Dropouts in sublingual allergen immunotherapy trials - a systematic review | Q38199748 | ||
| Relation between eosinophilic esophagitis and oral immunotherapy for food allergy: a systematic review with meta-analysis | Q38248758 | ||
| The future of biologics: applications for food allergy | Q38348057 | ||
| Treatment of peanut allergy with rush immunotherapy | Q41111237 | ||
| Peanut oral immunotherapy modifies IgE and IgG4 responses to major peanut allergens | Q42132385 | ||
| Adverse reactions during peanut oral immunotherapy home dosing | Q42951847 | ||
| Engineered recombinant peanut protein and heat-killed Listeria monocytogenes coadministration protects against peanut-induced anaphylaxis in a murine model | Q44355416 | ||
| Persistent protective effect of heat-killed Escherichia coli producing "engineered," recombinant peanut proteins in a murine model of peanut allergy | Q44504353 | ||
| Estimating the economic burden of food-induced allergic reactions and anaphylaxis in the United States | Q44964974 | ||
| Oral desensitization as a useful treatment in 2-year-old children with cow's milk allergy | Q45874463 | ||
| Clinical predictors for favorable outcomes in an oral immunotherapy program for IgE-mediated cow's milk allergy | Q46388294 | ||
| Tolerance to extensively heated milk in children with cow's milk allergy. | Q50779129 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 28 | |
| P577 | publication date | 2016-04-01 | |
| P1433 | published in | Current Allergy and Asthma Reports | Q2246111 |
| P1476 | title | Current and Emerging Therapies for IgE-Mediated Food Allergy | |
| P478 | volume | 16 |
| Q39325571 | Asthma, Food Allergy, and How They Relate to Each Other |
| Q52606248 | Current perspectives on tree nut allergy: a review. |
| Q38742430 | Epigenetics and allergy: from basic mechanisms to clinical applications. |
| Q39094939 | Immunomodulating peptides for food allergy prevention and treatment |
| Q36256005 | Improvement of Therapeutic Efficacy of Oral Immunotherapy in Combination with Regulatory T Cell-Inducer Kakkonto in a Murine Food Allergy Model |
| Q39314225 | Patient-Centered Outcomes in Food Allergy |
| Q49956390 | Preparation and Analysis of Peanut Flour Used in Oral Immunotherapy Clinical Trials |
| Q48093883 | The role of basophils as innate immune regulatory cells in allergy and immunotherapy |
Search more.